earningsconfidence high
Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance
Eikon Therapeutics, Inc.
2026-Q1 EPS reported
-$2.46
- Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.
- Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.
- EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.
- EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.
- EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO.
item 2.02item 7.01item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.